pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
HER2 · news · pharmadog
← back to HER2
News · HER2
124
stories
May 7, 26
Dr Sznol on Optimal Treatment Sequencing in Melanoma
onclive
May 7, 26
Dr Mauro on the Significance of Alternative TKI Formulations in CML
onclive
May 7, 26
Dr Olawaiye on the FDA Approval of Relacorilant Plus Nab-Paclitaxel in PROC
onclive
May 7, 26
Sylvester Comprehensive Cancer Center Identifies a Screening Gap to Prevent a Type of Leukemia in the U.S.
onclive
May 7, 26
ASCO 2026 TNBC Deep Dive: Breast Cancer Experts Preview Practice-Informing Studies
onclive
May 7, 26
Track the Lung Cancer Abstracts That are Gaining Attention at ASCO 2026
onclive
May 7, 26
HERIZON-GEA-01 Study Design, Geographic Distribution, and PD-L1 Testing Considerations
onclive
May 7, 26
Approaching First-Line Treatment in PD-L1 CPS <1 HER2-Positive GEA
onclive
May 7, 26
Reigniting Your Curiosity During Fellowship
onclive
May 7, 26
Angelini fortifies neurology portfolio with $4.1B buyout of Catalyst
endpoints
May 6, 26
Dr McGregor on the DAD-IO Trial of Sacituzumab Govitecan and EV in Metastatic Urothelial Carcinoma
onclive
May 6, 26
Neoadjuvant T-DXd Followed by THP Improves RCB in HER2+ Breast Cancer
onclive
May 6, 26
Dr Lee on Research Collaborations Studying PD-L1 as a Biomarker in NSCLC
onclive
May 6, 26
Dr Chari on Frontline Combinations and Transplant Approaches in Multiple Myeloma
onclive
May 6, 26
Cases and Conversations™: Next-Generation Pathology Advances and Considerations for Precision Care in Non–Small Cell Lung Cancer
onclive
May 6, 26
Dr Herrera on the Significance of the FDA Approval of Nivolumab Plus AVD for Classical Hodgkin Lymphoma
onclive
May 6, 26
Dr Sznol on Biomarkers of Response in Metastatic Melanoma
onclive
May 6, 26
Transformational Utah Investment in Artificial Intelligence and Computing to Advance Health and Discovery
onclive
May 6, 26
ASCO 2026 HR+ and HER2+ Breast Cancer Preview: Read up on the Insights to Know Before You Go
onclive
May 6, 26
Disease Assessment and Mutational Testing in Progressive CLL
onclive
May 6, 26
Clinical Scenario Presentation and Treatment Approach for Progressive Disease
onclive
May 6, 26
Dr Pant on the Mechanism of Action of Daraxonrasib in PDAC
onclive
May 5, 26
Dr Cohen on Frontline Chemotherapy Selection in Metastatic Pancreatic Cancer
onclive
May 5, 26
Dr Pant on Managing Toxicities With Daraxonrasib in PDAC
onclive
May 5, 26
Breast Cancer Experts Preview Abstracts to Watch at the 2026 ESMO Breast Cancer Congress
onclive
May 5, 26
The Type of Fat—Not the Amount—Fuels Pancreatic Cancer
onclive
May 5, 26
Dr McGregor on Key End Points of the STRIKE Trial of Tivozanib Plus Pembrolizumab in RCC
onclive
May 5, 26
Dr Kuykendall on the Evolving JAK Inhibitor and Transplant Considerations in Myelofibrosis
onclive
May 5, 26
New Endometrial Targets Beyond HER2
onclive
May 5, 26
Coordinating Care in Multiple Myeloma Across Practice Settings
onclive
← prev
page 4 of 5
next →
